Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

161. Managing Menopause Chapter 4 Vasomotor Symptoms

Managing Menopause Chapter 4 Vasomotor Symptoms Managing Menopause Chapter 4 Vasomotor Symptoms - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S31–S34 Managing Menopause Chapter 4 Vasomotor Symptoms DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. VMS affect 60% to 80% of women entering menopause. 1 Hot flashes are common (...) in the perimenopausal transition, when ovarian activity may be intermittent, and they have also been documented during the luteal and menstrual phases of the cycle in women with premenstrual dysphoric disorder. 2 After menopause, it is important to be alert to atypical features or to a lack of response to effective therapy, which might indicate an alternative cause of the symptoms. The differential diagnosis includes hyperthyroidism, anxiety, panic attack, hypertension, emotional flushing, neurologic flushing

2014 Society of Obstetricians and Gynaecologists of Canada

162. Managing Menopause Chapter 7 Ongoing Management of Menopausal Women and Those With Special Considerations

Managing Menopause Chapter 7 Ongoing Management of Menopausal Women and Those With Special Considerations Managing Menopause Chapter 7 Ongoing Management of Menopausal Women and Those With Special Considerations - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S51–S58 Managing Menopause Chapter 7 Ongoing Management of Menopausal Women and Those With Special Considerations DOI: To view (...) the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Figures Figure 7.1 The Stages of Reproductive Aging Workshop + 10 staging system for reproductive aging in women The goal of this chapter is to give practical tips to health care providers for the management of symptomatic women during and after the menopausal transition, concerning mostly the initiation and follow-up of HT. The reader may refer to previous chapters for more extensive literature review

2014 Society of Obstetricians and Gynaecologists of Canada

163. Managing Menopause Chapter 5 Urogenital Health

Managing Menopause Chapter 5 Urogenital Health Managing Menopause Chapter 5 Urogenital Health - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S35–S41 Managing Menopause Chapter 5 Urogenital Health DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. The vagina, lower urinary tract, and pelvic floor have the same embryologic (...) origin, and therefore all contain estrogen receptors and undergo atrophy in the estrogen-deficient state of menopause. The concept of urogenital aging encompasses the altered structure and function of the urogenital tissues under the combined influence of estrogen loss from menopause and tissue aging. Although tissue aging is both insidious and inevitable, the effect of estrogen loss on the urogenital tissues is relatively rapid and, at least to some extent, reversible with ET. To access this article

2014 Society of Obstetricians and Gynaecologists of Canada

164. Managing Menopause Chapter 8 Sexuality and Menopause

Managing Menopause Chapter 8 Sexuality and Menopause Managing Menopause Chapter 8 Sexuality and Menopause - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S59–S73 Managing Menopause Chapter 8 Sexuality and Menopause DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Figures Figure 8.1 Sexual problems and personal distress (...) by age In gynaecologic practice many peri- and postmenopausal women present to the physician with new complaints of changes in sexual desire or pain with intercourse that affects their relationships and quality of life. 1,2 Postmenopausal women are interested in sex for physical pleasure, intimacy, and expression of love, as well as to please their partner. 3 Maintenance of sexuality is important for the well-being of women as they navigate the emotional and physical challenges of menopause. 2,4

2014 Society of Obstetricians and Gynaecologists of Canada

165. Managing Menopause Chapter 9 Complementary and Alternative Medicine (CAM)

Managing Menopause Chapter 9 Complementary and Alternative Medicine (CAM) Managing Menopause Chapter 9 Complementary and Alternative Medicine (CAM) - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S74–S80 Managing Menopause Chapter 9 Complementary and Alternative Medicine (CAM) DOI: To view the full text, please login as a subscribed user or . Click to view the full text

2014 Society of Obstetricians and Gynaecologists of Canada

166. Managing Menopause Chapter 6 Prescription Therapeutic Agents Full Text available with Trip Pro

Managing Menopause Chapter 6 Prescription Therapeutic Agents Managing Menopause Chapter 6 Prescription Therapeutic Agents - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S42–S50 Managing Menopause Chapter 6 Prescription Therapeutic Agents DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. In November 1929, clinicians

2014 Society of Obstetricians and Gynaecologists of Canada

167. Osteoporosis in Menopause

Osteoporosis in Menopause Osteoporosis in Menopause - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Pages 839–840 Osteoporosis in Menopause PRINCIPAL AUTHORS, x Aliya Khan , MD Hamilton ON x Michel Fortier , MD Quebec QC x MENOPAUSE AND OSTEOPOROSIS WORKING GROUP x Michel Fortier , MD (Co-Chair) x Michel Fortier , x Robert Reid , MD (Co-Chair) x Robert Reid , x Beth L. Abramson , MD x Beth L. Abramson , x (...) osteoporosis. Evidence Published literature was retrieved through searches of PubMed and The Cochrane Library on August 30 and September 18, 2012, respectively. The strategy included the use of appropriate controlled vocabulary (e.g., oteoporosis, bone density, menopause) and key words (e.g., bone health, bone loss, BMD). Results were restricted to systematic reviews, practice guidelines, randomized and controlled clinical trials, and observational studies published in English or French. The search

2014 Society of Obstetricians and Gynaecologists of Canada

168. Salivary hormone testing for menopausal women

Salivary hormone testing for menopausal women Salivary hormone testing for menopausal women Salivary hormone testing for menopausal women Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Salivary hormone testing for menopausal women. Lansdale: HAYES, Inc.. Directory Publication. 2013 Authors' conclusions Salivary hormone testing (SHT) is used to measure levels (...) of hormones, including estrogens, progestogens, androgens, and cortisol. Compared with hormone testing in blood, salivary hormone testing is noninvasive and saliva can be collected by patients at home. Salivary hormone testing is often recommended for women who receive hormone replacement therapy, especially women who receive compounded hormone preparations. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Female; Hormones; Humans; Menopause

2013 Health Technology Assessment (HTA) Database.

169. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. Full Text available with Trip Pro

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention.To report a comprehensive, integrated overview of findings from the 2 Women's Health Initiative (WHI) hormone therapy trials with extended postintervention follow-up.A total of 27,347 postmenopausal women

2013 JAMA Controlled trial quality: predicted high

170. Morphology of Mandibular Inferior Cortex in Panoramic Radiograph Can Help Diagnose Osteoporosis in Post Menopausal Women

Morphology of Mandibular Inferior Cortex in Panoramic Radiograph Can Help Diagnose Osteoporosis in Post Menopausal Women UTCAT2545, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Morphology of Mandibular Inferior Cortex in Panoramic Radiograph Can Help Diagnose Osteoporosis in Post Menopausal Women Clinical Question In postmenopausal women can the morphology of the mandibular inferior cortex be used as a screening (...) postmenopausal women (Group A) and 157 Post Menopausal women with histories of hysterectomy, oophorectomy, or estrogen use (Group B). Subjects had a diagnostic performances of panoramic measurements, Bone Mineral Density (BMD) at the lumber Spine (L2-L4) was measured by Dual –Energy X-ray Absorptiometry In vivo study Clinical trial Key results Dual Energy X ray Absorptiometry (DXA) of the Lumbar Spines (Bone Mineral Density) is the Gold Standard for Diagnosing Osteoporosis. Study group was categorized into 3

2013 UTHSCSA Dental School CAT Library

171. Bioidentical hormone replacement therapy for menopausal symptoms

Bioidentical hormone replacement therapy for menopausal symptoms Bioidentical hormone replacement therapy for menopausal symptoms Bioidentical hormone replacement therapy for menopausal symptoms Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bioidentical hormone replacement therapy for menopausal symptoms. Lansdale: HAYES, Inc.. Directory Publication. 2013 (...) Authors' conclusions Bioidentical hormone replacement therapy (BHRT) includes both "natural", compounded hormones obtained from compounding pharmacies and Food and Drug Administration-approved hormones that are identical to endogenous hormones. BHRT is used to treat the symptoms of menopause, including: vasomotor symptoms, urogenital symptoms, and bone loss. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Hormone Replacement Therapys

2013 Health Technology Assessment (HTA) Database.

172. Acupuncture for menopausal hot flushes. Full Text available with Trip Pro

Acupuncture for menopausal hot flushes. Hot flushes are the most common menopausal vasomotor symptom. Hormone therapy (HT) has frequently been recommended for relief of hot flushes, but concerns about the health risks of HT have encouraged women to seek alternative treatments. It has been suggested that acupuncture may reduce hot flush frequency and severity.To determine whether acupuncture is effective and safe for reducing hot flushes and improving the quality of life of menopausal women (...) for Complementary and Alternative Medicine (NCCAM), BIOSIS, AMED, Acubriefs, and Acubase.Randomized controlled trials comparing any type of acupuncture to no treatment/control or other treatments for reducing menopausal hot flushes and improving the quality of life of symptomatic perimenopausal/postmenopausal women were eligible for inclusion.Sixteen studies, with 1155 women, were eligible for inclusion. Three review authors independently assessed trial eligibility and quality, and extracted data. We pooled

2013 Cochrane

173. Abnormal Uterine Bleeding in Pre-Menopausal Women

Abnormal Uterine Bleeding in Pre-Menopausal Women 404 Toggle navigation Toggle search Keyword search language Keyword search 404 Error Page/Asset Not Found The Society of Obstetricians and Gynaecologists of Canada (SOGC) {1} {1} {1}

2013 Society of Obstetricians and Gynaecologists of Canada

174. Global Consensus Statement on Menopausal Hormone Therapy

Global Consensus Statement on Menopausal Hormone Therapy CLIMACTERIC 2013;16:203–204 © 2013 International Menopause Society and Elsevier Inc. DOI: 10.3109/13697137.2013.771520 This Statement is being simultaneously published in the journals Climacteric and Maturitas , on behalf of the International Menopause Society and The European Menopause and Andropause Society, respectively. Correspondence: T. J. de Villiers, MediClinic Panorama, Parow 7500, South Africa Global Consensus Statement (...) on Menopausal Hormone Therapy T. J. de Villiers , M. L. S. Gass * , C. J. Haines † , J. E. Hall ‡ , R. A. Lobo * * , D. D. Pierroz † † and M. Rees ‡ ‡ MediClinic Panorama and Department of Obstetrics and Gynecology, Stellenbosch University, Cape Town, South Africa; * Department of Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine, Cleveland, OH, USA; † Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Prince of Wales

2013 The North American Menopause Society

175. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society

Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society Menopause: The Journal of The North American Menopause Society Vol. 20, No. 9, pp. 888/902 DOI: 10.1097/gme.0b013e3182a122c2 * 2013 by The North American Menopause Society POSITION STATEMENT Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society Abstract Objective: To update and expand the previous position statement (...) of The North American Menopause Society (NAMS) on the management of symptomatic vulvovaginal atrophy (VVA) in postmenopausal women. Methods:NAMSsearchedPubMedformedicalliteratureonVVApublishedsincetheir2007positionstatement on the role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women. A panel of ac- knowledged experts in the field of genitourinary health reviewed the literature to evaluate new evidence on local estrogen as well as on other management options available

2013 The North American Menopause Society

176. Osphena (ospemifene) - To treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause

Osphena (ospemifene) - To treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Osphena (ospemifene) Oral Tablets Company: Shionogi Inc. Application No.: 203505 Approval Date: 2/26/2013 Persons with disabilities having problems accessing the PDF files below may

2013 FDA - Drug Approval Package

177. Duavee (conjugated estrogens / bazedoxifene) - To treat moderate-to-severe hot flashes (vasomotor symptoms) associated with menopause and to prevent osteoporosis after menopause

Duavee (conjugated estrogens / bazedoxifene) - To treat moderate-to-severe hot flashes (vasomotor symptoms) associated with menopause and to prevent osteoporosis after menopause Drug Approval Package: Duavee NDA #022247 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Duavee (conjugated estrogens and bazedoxifene) Company: Wyeth Pharmaceuticals, Inc. Application No.: 022247 Approval Date: 10/3/2013 Persons with disabilities having problems accessing

2013 FDA - Drug Approval Package

178. Systematic review: Hormone therapy not recommended for chronic disease prevention in menopausal women

Systematic review: Hormone therapy not recommended for chronic disease prevention in menopausal women Hormone therapy not recommended for chronic disease prevention in menopausal women | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Hormone therapy not recommended for chronic disease prevention in menopausal women Article Text Prevention Systematic review Hormone therapy not recommended for chronic disease prevention in menopausal women Nanette K

2013 Evidence-Based Medicine

179. Efficacy of Cognitive Behavioral Therapy and Physical Exercise in Alleviating Treatment-Induced Menopausal Symptoms in Patients With Breast Cancer: Results of a Randomized, Controlled, Multicenter Trial (Abstract)

Efficacy of Cognitive Behavioral Therapy and Physical Exercise in Alleviating Treatment-Induced Menopausal Symptoms in Patients With Breast Cancer: Results of a Randomized, Controlled, Multicenter Trial The purpose of our study was to evaluate the effect of cognitive behavioral therapy (CBT), physical exercise (PE), and of these two interventions combined (CBT/PE) on menopausal symptoms (primary outcome), body image, sexual functioning, psychological well-being, and health-related quality (...) of life (secondary outcomes) in patients with breast cancer experiencing treatment-induced menopause.Patients with breast cancer reporting treatment-induced menopausal symptoms (N=422) were randomly assigned to CBT (n=109), PE (n=104), CBT/PE (n=106), or to a waiting list control group (n=103). Self-report questionnaires were completed at baseline, 12 weeks, and 6 months. Multilevel procedures were used to compare the intervention groups with the control group over time.Compared with the control group

2012 EvidenceUpdates Controlled trial quality: uncertain

180. Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: U.S. Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: U.S. Preventive Services Task Force Recommendation Statement. Update of the 2005 U.S. Preventive Services Task Force (USPSTF) recommendation statement on hormone therapy for the prevention of chronic conditions in postmenopausal women.The USPSTF commissioned a review of the literature to update evidence about the benefits and harms of using menopausal hormone therapy to prevent chronic conditions, as well as whether (...) the benefits and harms of hormone therapy differ by population subgroups defined by age; the presence of comorbid medical conditions; and the type, dose, and method of hormonal delivery.This recommendation applies to postmenopausal women who are considering hormone therapy for the primary prevention of chronic medical conditions. It does not apply to women who are considering hormone therapy for the management of menopausal symptoms, such as hot flashes or vaginal dryness. It also does not apply to women

2012 Annals of Internal Medicine